SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Qian Hong)
 

Sökning: WFRF:(Qian Hong) > Leukotriene signali...

Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia

Dolinska, Monika, 1989- (författare)
Piccini, Alexandre (författare)
Wong, Wan Man (författare)
visa fler...
Gelali, Eleni (författare)
Johansson, Anne-Sofie (författare)
Klang, Johannis (författare)
Xiao, Pingnan (författare)
Yektaei-Karin, Elham (författare)
Strömberg, Ulla Ohlsson (författare)
Mustjoki, Satu (författare)
Stenke, Leif (författare)
Ekblom, Marja (författare)
Qian, Hong (författare)
visa färre...
 (utgivare)
Elsevier, 2017
2017
Engelska.
Ingår i: Biochemical and Biophysical Research Communications - BBRC. - 0006-291X. ; 490:2, 378-384
  • swepub:Mat__t
Abstract Ämnesord
Stäng  
  • Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) are remarkably effective inducing deep molecular remission in most patients. However, they are less effective to eradicate the leukemic stem cells (LSC), resulting in disease persistence. Therefore, there is great need to develop novel therapeutic strategies to specifically target the LSC. In an experimental mouse CML model system, the leukotriene pathway, and specifically, the expression ALOX5, encoding 5-lipoxygenase (5-LO), has been reported as a critical regulator of the LSC. Based on these results, the 5-LO inhibitor zileuton has been introduced in clinical trials as a therapeutic option to target the LSC although its effect on primary human CML LSC has not been studied. We have here by using multiplex single cell PCR analyzed the expression of the mediators of the leukotriene pathway in bone marrow (BM) BCR-ABL(+)CD34(+)CD38(-) cells at diagnosis, and found low or undetectable expression of ALOX5. In line with this, zileuton did not exert significant overall growth inhibition in the long-term culture-initiating cell (LTC-IC) and colony (CFU-C) assays of BM CD34(+)CD38(-) cells from 7 CML patients. The majority of the single leukemic BCR-ABL(+)CD34(+)CD38(-) cells expressed cysteinyl leukotriene receptors CYSLTI and CYSLT2. However, montelukast, an inhibitor of CYSLTI, also failed to significantly suppress CFU-C and LTC-IC growth. These findings indicate that targeting ALOX5 or CYSLTI signaling with leukotriene antagonists, introduced into the clinical practice primarily as prophylaxis and treatment for asthma, may not be a promising pharmacological strategy to eradicate persisting LSC in CML patients. (C) 2017 The Author(s). Published by Elsevier Inc.

Ämnesord

Medical and Health Sciences  (hsv)
Clinical Medicine  (hsv)
Hematology  (hsv)
Medicin och hälsovetenskap  (hsv)
Klinisk medicin  (hsv)
Hematologi  (hsv)

Nyckelord

Leukotriene
Leukemic stem cells
Chronic myeloid leukemia
LTC-IC

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy